We showed that a Herceptin-conjugated liposomal formulation loaded with siRNA-LCN2 offers a potential dual therapeutic strategy against HER2+ IBC tumor emboli, which closely mimics patient-derived IBC disease. Here, LCN2 is linked to inflammatory breast carcinoma.